BACKGROUND: A significant number of patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs) present with metastatic disease and with unknown primary in about 15% of cases. MATERIALS AND METHODS: We analyzed 163 primaries of GEP NET and 115 metastases for expression of caudal type homebox 2 (CDX2), estrogen receptor (ER), progesterone receptor (PR), somatostatin receptor 2a (SSTR2a) and Ki67. RESULTS: PR was most often positive in pancreatic NET and only rarely in non-pancreatic NET (p<0.001). ER was more frequently expressed in non-pancreatic NET (p<0.001) and was more often positive in females than males (p=0.019). CDX2 was positive in all primaries of the duodenum, ileum and appendix, but was also detected in 24% of metastases with pancreatic primary. SSTR2a and Ki67 did not differ significantly between primaries and metastases. CONCLUSION: Our data substantiate the value of PR, ER and CDX2 in GEP NET, and steroid hormone receptors, being differentially expressed in male and female patients. Differences between primaries and metastases were small but potentially relevant. Copyright
BACKGROUND: A significant number of patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs) present with metastatic disease and with unknown primary in about 15% of cases. MATERIALS AND METHODS: We analyzed 163 primaries of GEP NET and 115 metastases for expression of caudal type homebox 2 (CDX2), estrogen receptor (ER), progesterone receptor (PR), somatostatin receptor 2a (SSTR2a) and Ki67. RESULTS:PR was most often positive in pancreatic NET and only rarely in non-pancreatic NET (p<0.001). ER was more frequently expressed in non-pancreatic NET (p<0.001) and was more often positive in females than males (p=0.019). CDX2 was positive in all primaries of the duodenum, ileum and appendix, but was also detected in 24% of metastases with pancreatic primary. SSTR2a and Ki67 did not differ significantly between primaries and metastases. CONCLUSION: Our data substantiate the value of PR, ER and CDX2 in GEP NET, and steroid hormone receptors, being differentially expressed in male and female patients. Differences between primaries and metastases were small but potentially relevant. Copyright
Authors: Andreas Selberherr; Oskar Koperek; Philipp Riss; Christian Scheuba; Reto Kaderli; Aurel Perren; Bruno Niederle Journal: Endocr Pathol Date: 2019-03 Impact factor: 3.943
Authors: Nadine Zimmermann; Juliana Knief; Tim Kacprowski; Pamela Lazar-Karsten; Tobias Keck; Franck Billmann; Sebastian Schmid; Kim Luley; Hendrik Lehnert; Georg Brabant; Christoph Thorns Journal: Oncotarget Date: 2018-06-19
Authors: Anela Blažević; Tessa Brabander; Wouter T Zandee; Johannes Hofland; Gaston J H Franssen; Marie-Louise F van Velthuysen; Richard A Feelders; Wouter W De Herder Journal: Cancers (Basel) Date: 2021-01-25 Impact factor: 6.639
Authors: Anela Blažević; Anand M Iyer; Marie-Louise F van Velthuysen; Johannes Hofland; Lindsey Oudijk; Wouter W de Herder; Leo J Hofland; Richard A Feelders Journal: J Clin Endocrinol Metab Date: 2022-04-19 Impact factor: 6.134
Authors: Alberto Puccini; Kelsey Poorman; Mohamed E Salem; Davide Soldato; Andreas Seeber; Richard M Goldberg; Anthony F Shields; Joanne Xiu; Francesca Battaglin; Martin D Berger; Ryuma Tokunaga; Madiha Naseem; Afsaneh Barzi; Syma Iqbal; Wu Zhang; Shivani Soni; Jimmy J Hwang; Philip A Philip; Stefania Sciallero; W Michael Korn; John L Marshall; Heinz-Josef Lenz Journal: Clin Cancer Res Date: 2020-09-03 Impact factor: 12.531
Authors: Michelle X Yang; Ryan F Coates; Abiy Ambaye; Valerie Cortright; Jeannette M Mitchell; Alexa M Buskey; Richard Zubarik; James G Liu; Steven Ades; Maura M Barry Journal: Biomark Res Date: 2018-04-18